1437 related articles for article (PubMed ID: 34093592)
21. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
[TBL] [Abstract][Full Text] [Related]
22. CAR T-cells profiling in carcinogenesis and tumorigenesis: An overview of CAR T-cells cancer therapy.
Samadani AA; Keymoradzdeh A; Shams S; Soleymanpour A; Rashidy-Pour A; Hashemian H; Vahidi S; Norollahi SE
Int Immunopharmacol; 2021 Jan; 90():107201. PubMed ID: 33249047
[TBL] [Abstract][Full Text] [Related]
23. CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges.
Khorasani ABS; Sanaei MJ; Pourbagheri-Sigaroodi A; Ghaffari SH; Bashash D
Int Immunopharmacol; 2021 Dec; 101(Pt B):108260. PubMed ID: 34678690
[TBL] [Abstract][Full Text] [Related]
24. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
[TBL] [Abstract][Full Text] [Related]
25. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
26. CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar.
Chen K; Liu ML; Wang JC; Fang S
Biomol Biomed; 2024 May; 24(3):465-476. PubMed ID: 37877819
[TBL] [Abstract][Full Text] [Related]
27. Paving New Roads for CARs.
Hyrenius-Wittsten A; Roybal KT
Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
[TBL] [Abstract][Full Text] [Related]
29. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
30. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
Chen J; Jiang H
Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
[TBL] [Abstract][Full Text] [Related]
31. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
Front Immunol; 2021; 12():799206. PubMed ID: 34975912
[TBL] [Abstract][Full Text] [Related]
32. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
Das S; Valton J; Duchateau P; Poirot L
Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
[TBL] [Abstract][Full Text] [Related]
33. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
34. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
35. CAR-T cell therapy: a potential new strategy against prostate cancer.
Schepisi G; Cursano MC; Casadei C; Menna C; Altavilla A; Lolli C; Cerchione C; Paganelli G; Santini D; Tonini G; Martinelli G; De Giorgi U
J Immunother Cancer; 2019 Oct; 7(1):258. PubMed ID: 31619289
[TBL] [Abstract][Full Text] [Related]
36. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.
Alcantara M; Du Rusquec P; Romano E
Oncoimmunology; 2020 Jun; 9(1):1777064. PubMed ID: 32934880
[TBL] [Abstract][Full Text] [Related]
37. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
[TBL] [Abstract][Full Text] [Related]
38. Next-generation CAR T cells to overcome current drawbacks.
Lundh S; Maji S; Melenhorst JJ
Int J Hematol; 2021 Nov; 114(5):532-543. PubMed ID: 32594314
[TBL] [Abstract][Full Text] [Related]
39. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
40. Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors.
Conejo-Garcia JR; Guevara-Patino JA
Immunol Invest; 2022 Nov; 51(8):2215-2225. PubMed ID: 35797428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
